Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia
Kings College Hospital, London, UK
Cancer Research UK Centre, University of Southampton, UK
Velindre Cancer Centre, Cardiff, UK
Austin Hospital, Melbourne, Victoria, Australia
Nottingham University Hospitals NHS Trust, UK
HELIOS-Klinikum Erfurt, Germany
BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany
Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Eberhard-Karls-University Tübingen, Germany
Roche Pharma AG, Grenzach-Wyhlen, Germany
F. Hoffmann-La Roche Ltd., Basel, Switzerland
F. Hoffmann-La Roche Ltd., Basel, Switzerland
Department of Medicine III, Ludwig-Maximilians-University, Munich, Germany
Vol. 104 No. 6 (2019): June, 2019